Simply Wall St.
Has Novartis’ 24.5% Surge Left Further Upside After Strong Pipeline and Cash Flow Gains?
📈
AI Sentiment
Highly Positive
8/10
Novartis AG News
Latest updates and market news for NVS
20 news
Dec 9 - Dec 15, 2025
Page 1
MT Newswires
Novartis Breaks Ground on North Carolina Manufacturing Hub
📊
AI Sentiment
Positive
7/10
Insider Monkey
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Novartis breaks ground on flagship manufacturing hub in North Carolina
📈
AI Sentiment
Highly Positive
8/10
Pharmaceutical Technology
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Sen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
How Novartis’ AI-Enabled Atopic Disease Alliance with Relation Therapeutics Will Impact Novartis (SWX:NOVN) Investors
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Tristan Imbert co-opted as Independent Director
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Novartis (SWX:NOVN) Valuation After Key Ianalumab Phase III Success and Expanded Itvisma FDA Approval
📊
AI Sentiment
Positive
7/10
Insider Monkey
Novartis AG (NVS) Announces US FDA Approval of Itvisma®
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Novartis Says 1 in 4 Breast Cancer Patients Treated With Kisqali Progression-Free Beyond 4 Years
âž–
AI Sentiment
Neutral
5/10
MT Newswires
Novartis Says Phase 3 Ianalumab Study Showed Extended Immune Thrombocytopenia Disease Control
📊
AI Sentiment
Positive
6/10
GuruFocus.com
Novartis Drops $1.7 Billion on AI Allergy Breakthrough
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Sen-Jam Pharmaceutical Appoints Global Life Sciences Leader Rute Fernandes as Executive Advisor to Accelerate Commercialization Pathways
📈
AI Sentiment
Highly Positive
9/10
GlobeNewswire
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
📈
AI Sentiment
Highly Positive
9/10
Share this news page